Overview
Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients
Status:
Unknown status
Unknown status
Trial end date:
2019-12-01
2019-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function in chinese, and which one could be better.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Shanghai 10th People's HospitalTreatments:
Benzbromarone
Febuxostat
Criteria
Inclusion Criteria:Chronic kidney disease patients with glomerular filtration rate (GFR,20-60ml/min) who match
one of the following criteria:
1. Gout
2. serum uric acid > 480umol/L
Exclusion Criteria:
1. GFR<20ml/min or GFR >60ml/min
2. Liver dysfunction (Aspartate transaminase or/and alanine aminotransferase exceed 2
times of normal range)
3. Urinary tract obstruction
4. unstable angina, heart failure (stage III-IV, NYHA), new stroke, need diuretics for
long-term treatment
5. Severe lung diseases or cancers
6. Pregnant woman or woman who prepare to be pregnant,nursing mothers
7. unable to sign informed consent form,or disagree with following-up